ArticleFrontiers in pharmacology2025
Analysis of serum amino acids and tryptophan metabolites to predict hepatic encephalopathy in portal hypertension patients receiving a transjugular intrahepatic portal shunt (TIPS).
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Identifying the shared genes and their related microRNAs, metabolites, and pathways in ischemic stroke and epilepsy.Scientific reports · 2026Article
- Unveiling biomarkers of telitacicept's efficacy in SLE treatment through proteomics and metabolomics.Frontiers in immunology · 2026Article
- Pretreatment of trans-ferulic acid improved neurotoxicity in a thioacetamide-induced hepatic encephalopathy rat model; participation of the MAPK/NF-κb signaling pathway.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The incidence of hepatic encephalopathy (HE) after transjugular intrahepatic portal shunt (TIPS) is over 30%, how to decrease the occurrence rate of HE is one of the most challenging issues after TIPS surgery. The aim of this study is to identify the potential biomarker that can predict the occurence of HE after TIPS in patients with portal hypertension (PH), and provide the theoretical support for early clinical diagnosis and prevention. Methods: A total of 50 patients with PH underwent TIPS were enrolled with completed clinical information in this study, and they were divided into two groups with or without the complications of HE. Results: We quantitatively determined 20 serum amino acids, and found that 4 amino acid levels were increased significantly in patients who complicated HE after TIPS. Screened by the specific screening criteria (VIP > 1.0; P < 0.05; FC > 1.5, or FC < 0.67) on MetaboAnalyst 5.0 on-line platform, tryptophan (TRP) were identified as the potential biomarker (50.31 μmol/L in non-HE group vs 100.21 μmol/L in HE group). Subsequently the detection of serum tryptophan metabolites revealed that the higher levels of kynurenine (KYN) and 2,3-Pyridinedicarboxylic acid (QA) were observed in the patients complicated HE after TIPS. ROC multivariate analysis indicated that the combination of TRP, KYN and QA provied the better predictive value for HE occurrence in PH patients underwent TIPS (AUC = 0.92). Discussion: This study provided the theoretical suggestion to the clinical doctor which the level of serum TRP/KYN/QA of patients should be detected before TIPS, and It is of great significance for patient prognosis and reducing the occurrence of HE after TIPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.